Equities analysts expect that Arcadia Biosciences Inc (NASDAQ:RKDA) will report $450,000.00 in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Arcadia Biosciences’ earnings, with the lowest sales estimate coming in at $400,000.00 and the highest estimate coming in at $500,000.00. Arcadia Biosciences posted sales of $440,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 2.3%. The company is expected to announce its next quarterly earnings report on Wednesday, March 25th.
On average, analysts expect that Arcadia Biosciences will report full year sales of $1.15 million for the current fiscal year, with estimates ranging from $1.10 million to $1.20 million. For the next financial year, analysts expect that the company will report sales of $8.55 million, with estimates ranging from $6.30 million to $10.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Arcadia Biosciences.
Arcadia Biosciences (NASDAQ:RKDA) last issued its quarterly earnings results on Wednesday, November 6th. The basic materials company reported ($2.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($1.27). The company had revenue of $0.39 million during the quarter, compared to analyst estimates of $0.31 million. Arcadia Biosciences had a negative net margin of 1,938.76% and a negative return on equity of 198.10%.
In other Arcadia Biosciences news, Director Kevin Comcowich bought 15,000 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were bought at an average price of $6.49 per share, for a total transaction of $97,350.00. Following the transaction, the director now owns 5,000 shares of the company’s stock, valued at approximately $32,450. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have acquired a total of 32,200 shares of company stock worth $188,076 in the last quarter. 3.30% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RKDA. Citadel Advisors LLC acquired a new stake in Arcadia Biosciences in the 2nd quarter valued at $32,000. Cambridge Investment Research Advisors Inc. bought a new position in shares of Arcadia Biosciences during the second quarter worth about $34,000. Squarepoint Ops LLC bought a new position in shares of Arcadia Biosciences during the third quarter worth about $124,000. Sabby Management LLC lifted its position in shares of Arcadia Biosciences by 150.0% during the third quarter. Sabby Management LLC now owns 50,000 shares of the basic materials company’s stock worth $234,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Arcadia Biosciences by 47.1% during the second quarter. Vanguard Group Inc. now owns 117,059 shares of the basic materials company’s stock worth $359,000 after purchasing an additional 37,472 shares during the last quarter. Institutional investors own 8.03% of the company’s stock.
RKDA stock traded up $0.21 during trading on Friday, hitting $5.42. The company had a trading volume of 172,571 shares, compared to its average volume of 1,262,908. The firm has a market cap of $45.15 million, a PE ratio of -1.01 and a beta of -2.98. Arcadia Biosciences has a 1-year low of $1.82 and a 1-year high of $10.40. The firm has a 50-day moving average price of $4.76 and a 200-day moving average price of $4.68. The company has a quick ratio of 5.27, a current ratio of 5.58 and a debt-to-equity ratio of 0.11.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.